- ►annals.org HJ Kwon, TR Cote, MS Cuffe, JM Kramer, MM … - Annals of internal medicine, 2003 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
Background: Etanercept and infliximab are US Food and Drug Administration– ... Cited by 247 - Related articles - BL Direct - All 8 versions
N Mohan, ET Edwards, TR Cupps, PJ Oliverio, … - Arthritis Care & Research - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 472 - Related articles - BL Direct - All 6 versions
- ►ahajournals.org ES Chung, M Packer, KH Lo, AA Fasanmade, … - Circulation, 2003 - Am Heart Assoc Methods and Results– One hundred fifty patients with stable New York Heart
Association class III or IV heart failure and left ventricular ejection fraction
≤35% were randomly assigned to receive placebo (n=49), infliximab 5 mg/kg ... Cited by 367 - Related articles - BL Direct - All 8 versions
SL Brown, MH Greene, SK Gershon, ET … - Arthritis Rheum, 2002 - bibliomed.bib.uniud.it Objective. Etanercept and infliximab are tumor necrosis factor (TNF) antagonists
that have been re- cently approved for the treatment of rheumatoid arthri- tis
(RA) and Crohn's disease (CD). This study was undertaken to investigate the ... Cited by 414 - Related articles - View as HTML - BL Direct - All 5 versions
- ►toodoc.com [PDF] F Wolfe, K Michaud - The American journal of medicine, 2004 - Elsevier Heart failure was more common among patients with rheumatoid arthritis (3.9% [n
= 461]) than in those with osteoarthritis (2.3% [n = 87]), after adjusting for
differences in demographic characteristics. Patients with rheumatoid ... Cited by 183 - Related articles - All 11 versions
JH Lee, NR Slifman, SK Gershon, ET Edwards … - Arthritis Care & Research - interscience.wiley.com Two tumor necrosis factor (TNF ) antagonists were recently licensed in the US.
Infliximab was licensed in 1998 for the treatment of Crohn's disease (CD), and
since 1999, it has been licensed in combination with methotrexate for ... Cited by 284 - Related articles - BL Direct - All 5 versions
M Debandt, O Vittecoq, V Descamps, X Le … - Clinical rheumatology, 2003 - Springer Abstract Anti-TNF-a therapies are promisingnew strategies in the treatment of
rheumatoid arthritis (RA). Despite good clinical efficacy and tolerance, the
possible occurrence of drug-induced autoimmune disorders re- mains a matter ... Cited by 113 - Related articles - BL Direct - All 3 versions
- ►switch-pharma.com [PDF] SD Anker, AJS Coats - International journal of cardiology, 2002 - Elsevier Two trial programmes testing an anti-cytokine medication in chronic heart
failure (CHF) have been halted. In the RENAISSANCE and RECOVER trials (the
combined analysis being termed RENEWAL), 2048 CHF patients were randomised ... Cited by 214 - Related articles - All 14 versions
NR Slifman, SK Gershon, JH Lee, ET … - Arthritis Care & Research - interscience.wiley.com Tumor necrosis factor (TNF ) has been implicated in the pathogenesis of certain
inflammatory diseases. Two TNF -neutralizing agents are licensed in the US.
Infliximab is licensed for the treatment of Crohn's disease (CD) and, when ... Cited by 232 - Related articles - BL Direct - All 3 versions
A Cheifetz, M Smedley, S Martin, M Reiter, G … - The American journal of gastroenterology, 2003 - nature.com The overall incidence of infusion reactions to infliximab was 6.1% (29 of 479)
of infusions, affecting 9.7% (16 of 165) of patients. Mild, moderate, or severe
acute reactions occurred in 3.1% (15 of 479), 1.2% (six of 479), and 1.0% ... Cited by 202 - Related articles - BL Direct - All 8 versions
